Six Questions For McKinsey Executives On Pharma’s Digital Experience

McKinsey & Co executives Vikas Bhadoria and Parag Patel, in an interview with Scrip, shared some key insights into pharma’s recent efforts around digitization and advanced analytics including the emergence of a Bayer site as a manufacturing ‘lighthouse’, Novartis’ Nerve Live platform and sales rep versus digital channel effectiveness.

Doctor — PHARMA HAS MADE DEFINITIVE STRIDES TOWARDS DIGITIZATION

Pharma may have been relatively sluggish off the block in terms of its overall digitization efforts compared with some other sectors, but several large drug firms are now increasingly keen to leverage digital and advanced analytics tools to drive efficiencies and crunch costs across operations.

Among other initiatives, companies are establishing or navigating data lakes, using digital channels to engage with healthcare professionals and creating manufacturing ‘lighthouses’ – plants that have successfully adopted and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

16 May 2025

• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

16 May 2025

• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.